Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs
CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things like inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.